Spyre Therapeutics, Inc. (SYRE)
Data as of , from SEC Form 4 filings.
Net insider selling (90d)Watch SYRE
See up to 3 months of SYRE. The 7-day demo opens the 1M and 3M ranges and puts SYRE on your watchlist.
Start 7-day demoLatest SYRE insider trades
About Spyre Therapeutics, Inc. (SYRE)
Spyre Therapeutics, Inc. is an SEC registrant, filing under CIK 0001636282, classified as pharmaceutical preparations. It is grouped with Health Care companies on this site.
SYRE Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 42 | 183,564 | $16.90M |
| Option exercise | 16 | 204,664 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
SYRE insider transactions (Form 4)
2141 Form 4 filings on record, the earliest from Oct 1, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Scott L. Burrows - Officer | Option exercise | Common Stock | 7,500 | $14.50 | $109K | |
| Scott L. Burrows - Officer | Open-market sale | Common Stock | 6,200 | $49.21 footnote F2 | $305K | |
| Scott L. Burrows - Officer | Open-market sale | Common Stock | 1,300 | $49.98 footnote F3 | $65K | |
| Scott L. Burrows - Officer | Option exercise | Stock Option (Right to Buy) | 7,500 | $0.00 | - | |
| ||||||
| Scott L. Burrows - Officer | Open-market sale | Common Stock | 2,300 | $40.56 footnote F2 | $93K | |
| Scott L. Burrows - Officer | Open-market sale | Common Stock | 200 | $41.66 footnote F3 | $8K | |
| Scott L. Burrows - Officer | Option exercise | Stock Option (Right to Buy) | 2,500 | $0.00 | - | |
| Scott L. Burrows - Officer | Option exercise | Common Stock | 2,500 | $14.50 | $36K | |
| ||||||
| Cameron Turtle - Officer | Open-market sale | Common Stock | 5,900 | $41.73 footnote F2 | $246K | |
| Cameron Turtle - Officer | Open-market sale | Common Stock | 9,100 | $42.49 footnote F4 | $387K | |
| ||||||
| Cameron Turtle - Officer | Open-market sale | Common Stock | 957 | $31.82 footnote F2 | $30K | |
| Cameron Turtle - Officer | Open-market sale | Common Stock | 14,043 | $32.87 footnote F5 | $462K | |
| ||||||
 Michael Thomas Henderson - Director | Other | Common Stock | 63,227 | $0.00 | - | |
| Cameron Turtle - Officer | Open-market sale | Common Stock | 10,995 | $28.73 footnote F2 | $316K | |
| Cameron Turtle - Officer | Open-market sale | Common Stock | 4,005 | $29.83 footnote F4 | $119K | |
| ||||||
| Cameron Turtle - Officer | Open-market sale | Common Stock | 28,155 | $23.13 footnote F2 | $651K | |
| Cameron Turtle - Officer | Open-market sale | Common Stock | 16,845 | $23.66 footnote F4 | $399K | |
| ||||||
| Scott L. Burrows - Officer | Open-market sale | Common Stock | 18,428 | $16.26 | $300K | |
 Jeffrey W. Albers - Director | Open-market sale | Common Stock | 6,700 | $36.76 | $246K | |
| Jeffrey W. Albers - Director | Open-market sale | Common Stock | 300 | $36.43 | $11K | |
| Sheldon Sloan - Officer | Grant or award | Stock Option (Right to Buy) | 400,000 | $0.00 | - | |
Item 1.01, 9.01
Item 7.01, 8.01, 9.01
Item 7.01, 8.01, 9.01
Item 2.02, 9.01
Recent SYRE Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| CAMERON TURTLE | Director, Officer | 45,000 | $4.01M | View on EDGAR | |
| HEIDY KING-JONES | Officer | 29,335 |
SYRE insider trading FAQ
What is the latest insider trade for SYRE?
Spyre Therapeutics, Inc. (SYRE) had 9 insider filings in the last 90 days, with the most recent on 2026-10-03. The full record for SYRE runs to 41 Form 4 filings, the earliest from 2024-10-01. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying SYRE stock?
No insider purchases of SYRE were filed in the last 90 days.
How many insiders are selling SYRE stock?
42 insider sales of SYRE were filed in the last 90 days, totaling $16.90M.
Where can I see SYRE SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects SYRE Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Heidy King-Jones view on EDGAR
- - Cameron Turtle view on EDGAR
- - Scott L. Burrows view on EDGAR
- - Heidy King-Jones view on EDGAR
- - Scott L. Burrows view on EDGAR
- - Cameron Turtle view on EDGAR
- - Jeffrey W. Albers view on EDGAR
- - Scott L. Burrows view on EDGAR
- - Cameron Turtle view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where SYRE's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow SYRE with a 7-day demo
- SYRE on your watchlist
- Every SYRE Form 4 filing on record
- Up to 3 months of SYRE price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
